Lumida
/HALO
⌘K
Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

HALO
$107.20USD+0.19%+0.20 today

MARKET CAP

12.2B

P/E (TTM)

20.0x

FWD P/E

10.6x

DAY RANGE

$106 – $108

52W RANGE

$61
$111

AI Summary

Stalk
StalkMedium

HALO remains in a constructive Stage 2 uptrend above rising EMAs but shows a Bullish Exhaustion signal and overbought readings. Price is currently pulling back into the 9- and 20-day EMAs, offering a potential re-entry zone. The medium-term bias stays bullish, yet short-term timing is unfavorable, so execution should be deferred until a clear hold or rejection off the EMA zone.

  • Total revenue up 48% YoY to $481 M, driven by 50% royalty growth.
  • FY26 revenue guide raised 31–37% to $1.835–1.91 B, reflecting robust outlook.
  • Weak book-to-price ratio indicates potential valuation headwinds.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$443.3M$660.1M$829.3M$1.0B$1.4B
YoY %+65.7%+48.9%+25.6%+22.4%+37.6%
P / Sales13.3x11.7x6.1x6.1x6.0x
EV / Sales15.1x13.9x7.9x7.7x7.6x
Gross Profit, Adj.$361.9M$520.8M$636.9M$855.9M$1.2B
YoY %+61.4%+43.9%+22.3%+34.4%+36.4%
Margin %81.6%78.9%76.8%84.3%83.6%
EV / Gross Profit18.5x17.6x10.3x9.1x9.1x
EBITDA, Adj.$278.9M$317.2M$422.4M$632.8M$890.6M
YoY %+89.0%+13.7%+33.2%+49.8%+40.7%
Margin %62.9%48.0%50.9%62.3%63.8%
EV / EBITDA24.0x29.0x15.5x12.3x12.0x
EBIT$275.9M$267.5M$337.6M$551.5M$517.7M
YoY %+91.3%-3.0%+26.2%+63.4%-6.1%
Margin %62.2%40.5%40.7%54.3%37.1%
EV / EBIT24.3x34.3x19.4x14.1x20.6x
Net Income$402.7M$202.1M$281.6M$444.1M$316.9M
YoY %+212.0%-49.8%+39.3%+57.7%-28.6%
Net Margin90.8%30.6%34.0%43.7%22.7%
EPS (GAAP)$2.74$1.44$2.10$3.43$2.56
YoY %+201.1%-47.4%+45.8%+63.3%-25.4%